Avanir Pharmaceuticals Announces Appointment of Corinne Nevinny to Board of Directors

 Avanir Pharmaceuticals Announces Appointment of Corinne Nevinny to Board of
                                  Directors

PR Newswire

ALISO VIEJO, Calif., March 11, 2013

ALISO VIEJO, Calif., March 11, 2013  /PRNewswire/ --Avanir Pharmaceuticals,
Inc. (NASDAQ: AVNR) today announced the appointment of Ms. Corinne Nevinny to
the company's board of directors. Ms. Nevinny, a seasoned life sciences
executive joins Avanir's board with broad healthcare industry experience
across multiple disciplines.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Ms. Nevinny is General Partner of LMNVC LLC, a privately held early stage
venture firm, which she founded in October 2010. Prior to that position, Ms.
Nevinny served as corporate vice president for seven years at Edwards
Lifesciences Corporation, a leading cardiovascular technology company. She
held several positions at the company including general manager of Cardiac
Surgery Systems and Vascular, president of Global Operations, and chief
financial officer and treasurer. Other positions Ms. Nevinny held included
vice president and chief financial officer of Tularik, Inc, a biotechnology
company acquired by Amgen and executive director in the health care group at
Warburg Dillon Read LLC, an investment bank.

Ms. Nevinny also serves on the board of directors of Onyx Pharmaceuticals,
Inc., Neurocrine Biosciences, Inc., as well as three private companies. Ms.
Nevinny received her undergraduate degree from Stanford University and her
M.B.A. from Harvard Business School.

"It is a pleasure to welcome Corinne to the Avanir Board," commented chairman
of the board, Craig Wheeler. "Her knowledge and expertise in finance,
operations, and the life sciences industry will complement the strengths and
talents of our existing board members."

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on
bringing innovative medicines to patients with central nervous system
disorders of high unmet medical need. As part of our commitment, we have
extensively invested in our pipeline and are dedicated to advancing medicines
that can substantially improve the lives of patients and their loved ones. For
more information about Avanir, please visit www.avanir.com.

AVANIR^® is a trademark or registered trademark of Avanir Pharmaceuticals,
Inc. in the United States and other countries.

^©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

SOURCE Avanir Pharmaceuticals, Inc.

Website: www.avanir.com
 
Press spacebar to pause and continue. Press esc to stop.